Unlocking Growth Opportunities in CNS Diseases€¦ · controlled opioid delivery platform y Strategic planning for a pain management device franchise y Commercialization strategy

Founded in 1992, Health Advances is a leading healthcare strategy firm advising

clients in the biopharma, diagnostic, device, and healthcare services sectors, as

well as investors and non-profit organizations. Healthcare executives rely on

our professionals to help them make confident decisions involving the greatest

challenges in the commercialization of medical technologies and services

throughout the world.

www.healthadvances.com

UnlockingGrowth

Opportunities inCNS Diseases

Core Competencies

y New Product Commercialization

y Product Forecasting

y Lifecycle Management Strategy

y Clinical Development Planning

y Portfolio Prioritization and Planning

y Franchise Strategy

y Corporate Strategy

y Pricing and Reimbursement

y Pharmacoeconomics

y Licensing and Acquisition

Identification

y Valuation and Due Diligence

Contact: [email protected]

BostonSan FranciscoWashington DCZurich

781-647-3435

www.healthadvances.com

Experience. It’s What Sets Us Apart.

Operating at the intersection of science, technology, and business strategy, Health Advances provides clients with innovative solutions based

on deep industry insight, analytical rigor, and an objective perspective. Example projects include:

Neurodegenerative Diseases

y Licensing strategy for a companyentering Alzheimer’s and Parkinson’smarkets

y Valuation models for multiple novel product concepts inParkinson’s disease

y Market assessment acrossneurodegenerative diseases to guide market entry

y Clinical trial strategy for Alzheimer’simaging agent

y Commercialization strategy andlaunch plan for respiratory supportdevice in ALS

y Development of a road map to expanda disease foundation’s relationshipwith commercial partners

y Strategy for advancing multi-disciplinary Parkinson’s care at a network of medical centers

Pain and Migraine

y Clinical, scientific, and competitiveanalysis of ion channel modulatorsfor use in chronic pain

y Development and co-positioningstrategy for neuropathic painfranchise

y Clinical development and market adoption strategy for a new pain product

y Acquisition diligence of anti-abuseformulation for a novel opioid

y Commercial assessment of acontrolled opioid delivery platform

y Strategic planning for a painmanagement device franchise

y Commercialization strategy forinhaled acute migraine therapy

Multiple Sclerosis

y Identification and prioritization of strategic initiatives for globalneuro-immunology franchise

y Market assessment of RNAi-basedtechnology for immune indications

y Elucidation of neurologist andpatient unmet needs through clinicvisits and on-site interviews

y Development costs and revenueprojections for prognostic andpredictive biomarkers

y US and EU commercializationstrategy for biosimilar interferon

y Launch plan and post-marketing trialdesign for a new injectable therapy

y Portfolio prioritization for an MRIimaging company

Psychiatric Illnesses

y Impact of efficacy and side effects onrevenue projections for generalizedanxiety disorder drug

y Transaction diligence for the acquisition of an antidepressantfranchise

y Revenue implications of increasing price in a highly competitive therapy class

y Strategy to increase CNS exposurethrough licensing and/or acquisition

y Forecast model utilizing detailedtreatment algorithms in depression and related conditions

y Prioritization of indications for a novel,sustained-release drug formulation

y Evaluation of trends in sales andmarketing costs

www.healthadvances.com